urolithiasis
UROLITHIASIS

Urolithiasis is the formation of urinary stones in the kidney, bladder and/or urethra.

The hallmark of obstruction in the ureter and renal pelvis is the sudden onset of excruciating, intermittent pain that radiates from the flank to the groin or to the genital area and inner thigh.

It is a painful urologic disorder that occurs in 12% of the global population and has a high recurrence rate among male patients.

Lower urinary tract symptoms that are associated with urolithiasis are urgency, frequency, urge incontinence and dysuria.

 

Surgical Intervention

Indications for active removal of stones:

  • Choice of treatment or patient preference
  • Comorbidity (eg hypertension, diabetes, obesity, dyslipidemia & gout)
  • Infection (eg pyelonephritis)
  • Obstruction caused by stones
  • Patients who are high-risk stone formers
  • Stone size of ≥6 mm after a period of watchful waiting
  • Symptomatic stones (eg presence of pain & hematuria)

Special problems encountered in stone removal:

  • Presence of caliceal diverticulum stones
  • Patient has horseshoe kidneys
  • Patients w/ uteropelvic junction (UPJ) obstruction

Extracorporeal Shockwave Lithotripsy (SWL)

  • A noninvasive & non aesthetic procedure, & the first choice of treatment for stone <1.5cm
  • Success depends on the efficacy of the lithotriper & some factors:
    • Size, composition & location of the stones
    • Patient’s habitus
    • Performance of extracorporeal shockwave lithotripsy (SWL)
  • Contraindications include:
    • Arterial aneurysms
    • Anatomical destruction distal to the stones
    • Bleeding diathesis
    • Infection
    • Severe skeletal malformations
    • Severe obesity
    • Uncontrolled urinary tract infections (UTIs)

Percutaneous Nephrolithotomy (PNL)  

  • Standard procedure for large renal calculi
  • Different rigid & flexible endoscopes are used in this procedure & it depends on the preference of the surgeon
  • Contraindications include:
    • Patients on anticoagulant therapy
    • Untreated UTI
    • Tumor in the presumptive access tract area
    • Potential malignant kidney tumor
    • Pregnancy
  • Complications associated w/ PNL:
    • Fever
    • Bleeding
    • Urinary leakage
    • Problems due to residual stones
    • Steinstrasse
      • Accumulation of stone fragments or stone gravel in the ureters
      • Major factor for its formation is the size of the stone
      • If asymptomatic, then conservative treatment is the initial option
      • For steinstrasse associated w/ UTI & fever, percutaneous nephrostomy is indicated
      • When large stones fragments are present, shockwave lithotripsy is indicated

Uteroscopic Lithotripsy - Rigid & Flexible (URS)

  • A minimally invasive procedure that is used for both ureteric & renal stones as an alternative treatment to extracorporeal shockwave lithotripsy (SWL)
  • Can be performed under a local, intravenous or general anesthesia
  • URS may be used in patients who had failed previous treatment attempts, stones too large for SWL, strictures, tumors, stones in children, those w/ bleeding disorders & obese
  • Stone-free rate status w/ larger stones is achieved earlier w/ URS
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.